22nd German Corporate Conference
January 17, 2023
Helen Giza, CEO and Chair of the Management Board
© Copyright
Safe harbor statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, many of which cannot be predicted with accuracy or might not even be anticipated. The Company has based these forward-looking statements on current estimates and assumptions which we believe are reasonable and which are made to the best of our knowledge. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic or competitive conditions, changes in reimbursement, regulatory compliance issues, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, cyber security issues and the availability of financing. Given these uncertainties, readers should not put undue reliance on any forward-looking statements. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA's (FMC AG & Co. KGaA) Annual Report on Form 20-F under the heading "Forward-Looking Statements" and under the headings in that report referred to therein, and in FMC AG & Co. KGaA's other reports filed with the Securities and Exchange Commission (SEC) and the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse).
Forward-looking statements represent estimates and assumptions only as of the date that they were made. The information contained in this presentation is subject to change without notice and the company does not undertake any duty to update the forward-looking statements, and the estimates and assumptions associated with them, except to the extent required by applicable law and regulations.
If not mentioned differently the term net income after minorities refers to the net income attributable to the shareholders of Fresenius Medical Care AG Co. KGaA. The term EMEA refers to the region Europe, Middle East and Africa. Amounts are in Euro if not mentioned otherwise.
Implementation of measures as presented herein may be subject to information & consultation procedures with works councils and other employee representative bodies, as per local laws and practice. Consultation procedures may lead to changes on proposed measures.
© Copyright
Leading vertically integrated dialysis provider
Products serving more than half
of the world's dialysis patients
Revenue | 3,743 |
€m |
757
19962021
Largest dialysis network worldwide
Revenue | 13,876 |
€m | |
396 | |
1996 | 2021 |
>150 m | ~ 50,000 |
dialyzers | dialysis machines |
As of December 31, 2021
1 out of 2
HD patients
worldwide
treated with an
FME machine
Products available
in 150
countries worldwide
>4,000
dialysis centers
Every 0.6
seconds we pro-
vide a dialysis
treatment
~345,000
dialysis patients
>50 m
dialysis
treatments
p. a.
Dialysis treat-
ments provided
in around 50
countries
Company Presentation | Page 3 |
Executing on key strategic priorities
Driving Value-based Care
- Improve clinical outcomes and quality of life for patients, reduce overall costs for payors and expand into CKD
- Leverage longstanding experience in Value-based Care and largest database of CKD patients in the industry
- For 2022, around USD 6 billion of Medical Costs Under Management are expected
Expanding Home dialysis
Aspirational target set:
25% of dialysis treatments in the U.S.
to be performed in a home setting by 2025
Company Presentation | Page 4 |
FME25 timeline and initiatives
FME25 framework
2021 | Alignment of new operating model |
Transition journey defined & first initiatives started | |
Phasing of investments & cost reductions
One-time investments (cumulative)
2022 | Transition to new operating model | |
Design further details of new operating model and | ||
initiate transformation | ||
- 175-245m
2022 - 40-70m
-
360-400m
2023 - 250m
- 450-500m
2024-2025
€ 500m
~2023 | Implementation of new operating model |
Start new external reporting and provide transparency | |
on new segments | |
2025 | Identify further growth and efficiency measures |
…within the new operating model beyond 2025
Cost reductions (cumulative)
Investments | € 109m | Progress |
9 month | ||
Cost reduction | € 51m | |
2022 | ||
Company Presentation | Page 5 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
FMC - Fresenius Medical Care AG & Co. KGaA published this content on 17 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 January 2023 10:39:04 UTC.